Claims for Patent: 10,675,296

Summary for Patent: 10,675,296

Title:	Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Abstract:	The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.
Inventor(s):	Nate Larson
Assignee:	Gilead Sciences Inc
Application Number:	US16/031,620
Patent Claims:	1. A composition comprising (i) a Compound 1 in an amount of from 1% to 10% w/w or a pharmaceutically acceptable salt thereof, and (ii) cyclodextrin in an amount of from 90% to 99% w/w; wherein the composition is a lyophilized composition. 2. The composition of claim 1, wherein the cyclodextrin is a beta-cyclodextrin. 3. The composition of claim 2, wherein the beta-cyclodextrin is sulfobutylalkylether-beta-cyclodextrin, betadex-sulfobutylether sodium, or hydroxypropyl-beta-cyclodextrin. 4. The composition of claim 2, wherein the beta-cyclodextrin is betadex-sulfobutylether sodium. 5. The composition of claim 1, comprising (i) the Compound 1 in an amount of from 1% to 5% w/w; and (ii) the cyclodextrin in an amount of from 95% to 99% w/w. 6. The composition of claim 5, wherein the cyclodextrin is betadex-sulfobutylether sodium. 7. The composition of claim 1, comprising (i) the Compound 1 in an amount of from 2% to 4% w/w; and (ii) the cyclodextrin in an amount of from 96% to 98% w/w. 8. The composition of claim 7, wherein the cyclodextrin is betadex-sulfobutylether sodium. 9. The composition of claim 1, comprising (i) the Compound 1 in an amount of from 3% to 3.5% w/w; and (ii) the cyclodextrin in an amount of from 96.5% to 97% w/w. 10. The composition of claim 9, wherein the cyclodextrin is betadex-sulfobutylether sodium. 11. The composition of claim 10, that is contained in a sealed vial. 12. The composition of claim 1, consisting essentially of the Compound 1 in an amount of 3.2% w/w, and the cyclodextrin betadex-sulfobutylether sodium in an amount of 96.8% w/w.